

ESO MASTERCLASS IN NEURO-ONCOLOGY: MULTIDISCIPLINARY MANAGEMENT OF ADULT BRAIN TUMOUR

20-22 September 2018 Milan, Italy

Chairs:

Endorsed by

P. Mortini, IT

G. Pesce, CH

Held in collaboration with









AIMS

The Masterclass offers plenary lectures on the state-of-the-art clinical evaluation and treatments with reference to clinical guidelines concluding with take-home messages. Participants will deliver case presentations within small groups and discuss them with the faculty. They will take advantage from internationally renowned experts in order to consolidate their knowledge and learn skills which are relevant to the management of difficult cases encountered in the daily clinical practice in neuro-oncology.

LEARNING OBJECTIVES

- Improve of neurologists, radiation oncologists, medical oncologists and surgical oncologists/neuro-surgeons skills
- Practicing case discussions
- Update on the current standards of neurosurgery with special focus on intraoperative imaging, monitoring and neuro-navigation.
- Improve the knowledge on current radiotherapy standards and techniques (IMRT, stereotactic radiosurgery, protons, etc.)
- Update on epidemiology, combination of radiotherapy with surgery and drug therapy, clinical trials management

MAIN TOPICS

- · Clinical management of patients with primary and metastatic brain tumors
- Technical improvements, altered fractionation, specific aspects of high precision radiotherapy, radiosurgery, chemo-sentitization and other aspects of medical therapy
- · Supportive treatments, symptom control both in palliative and curative intent

TEACHING FORMAT

The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and will conclude in take-home messages. The clinical sessions will be complemented by group discussions supported by the chairs and faculty. Participants will be encouraged to deliver case presentations within small groups and discuss these with the chairs and the faculty. All participants will reside at the course venue and participation will be expected to be present throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.

THE MASTERCLASS IS:

- · A 3-day residential educational event
- Full immersion
- · Clinically-oriented
- Multidisciplinary
- · Delivered by an international faculty of experts

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

- Neurologists, radiation oncologists, medical oncologists and surgical oncologists/neurosurgeons with at least 2 years experience in neurosurgery, radiotherapy or neuro-oncology.
- · Aged between 30 and 40 years
- Involvement in scientific activities (desirable)
- · Fluency in English

SCHOLARSHIPS

Two tuition scholarships in the amount of 350 EUR will be offered to applicants from Low and Middle Income Countries (http://bit.ly/2bBWnzX). In order to be considered for a scholarship, please submit a letter of motivation requesting consideration.

ACKNOWLEDGEMENT

Two travel grants were made available to participants through an unrestricted educational grant provided by **Varian**.

FACULTY (as of March 2018)

- L. Bertero, University and City of Health and Science Hospital of Turin, IT
- R. Bhangoo, King's College Hospital NHS Foundation Trust, London, UK
- D. Bosetti, Oncology Institute of Southern Switzerland, Bellinzona, CH
- **M. Brada**, University of Liverpool & Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK
- J. Capitanio, San Raffaele Hospital, Milan, IT
- A. Cianfoni, Neurocenter of Southern Switzerland, Lugano, CH
- C. Gamondi, Oncology Institute of Southern Switzerland, Bellinzona, CH
- R. Goldbrunner, University Hospital Cologne, DE
- W. Gulden-Sala, Oncology Institute of Southern Switzerland, Locarno, CH
- M. Hegi, Lausanne University Hospital (CHUV), Lausanne, CH
- S. lannaccone, San Raffaele Hospital, Milan, IT
- P. Mortini, Università Vita-Salute San Raffaele, Milan, IT
- G. Pesce, Oncology Institute of Southern Switzerland, Bellinzona, CH
- S. Presilla, Ente Ospedaliero Cantonale, Bellinzona, CH
- M. Reinert, Neurocenter of Southern Switzerland, Lugano, CH
- F. Roncaroli, University of Manchester, UK
- P. Roth, University Hospital Zurich, CH
- R. Rudà, University and City of Health and Science Hospital of Turin, IT
- R. Soffietti, University and City of Health and Science Hospital of Turin, IT

PROGRAMME

Group 3:

Thursday, 20 September					
	Arrival and registration				
13.00	Arrivat and registration				
13:30	Welcome and introduction to the course	G. Pesce, CH - P. Mortini, IT			
13:50	Welcome by the local Authority	Speaker to be confirmed			
14:00 O	VERVIEW ON BRAIN TUMORS	Chairs: P. Mortini, IT - G. Pesce, CH			
	Epidemiology and clinical prognostic factors of brain tumors	W. Gulden-Sala, CH			
14:30	Taking care of patients with primary and metastatic brain tumors, overview of the management strategies from the emergency room to the first line				
	therapy	G. Pesce, CH			
15:00 BRAIN METASTASES		Chairs: P. Mortini, IT - M. Reinert, Ch			
15:00	Neurosurgery of brain metastases: State of the art	M. Reinert, CH			
15:30	Coffee break				
16:00	Radiotherapy and radiosurgery for brain metastases: State of the art	M. Brada. UK			
16:30	Medical therapies for patient with brain metastases				
17:00 GROUP WORKSHOPS					
	Group 1:				
	• Clinical cases presentations by the participants Group 2:	Chair: G. Pesce, CH			
	• Clinical cases presentations by the participants	Chair: P. Mortini, IT			

• Clinical cases presentations by the participants Chair: R. Soffietti, IT

Friday, 21 September _____

16:00 Coffee break

8:30 INTRA-AXIAL PRIMARY BRAIN TUMORS:		Chairs: R. Bhangoo UK		
HIGH GRADE GLIOMAS AND LOWER GRADE GLIOMAS		G. Pesce, CH		
8:30 9:00		L. Bertero, ITA		
9.00	and new opportunities	M. Hegi, CH		
9:30	Neuro imaging - updates	A. Cianfoni. CH		
10:00	Coffee break			
10:30 11:00		R. Bhangoo, UK P. Roth, CH		
11:30		G. Pesce, CH		
12:00	Round table on rehabilitation: What's going on	C. Gamondi, CH - S. lannaccone, IT P. Mortini, IT - G. Pesce, CH		
13:00	Lunch			
14:00 DISCIPLINE ORIENTED WORKSHOPS				
	Group 1: • Surgery: Techniques to optimize tumor resection (intraoperative ultrasound, hydodissection, neuronavigation, brain Mapping)	Chairs: J. Capitanio,IT R. Bhangoo, UK		
	•	<i>Chairs:</i> M. Brada, UK - G. Pesce, CH S. Presilla, CH		
		Chairs: C. Gamondi, CH R. Rudà, IT		
15:00 15:30	Management of elderly patients with gliomas Treatment options for "inoperable" and recurrent	R. Rudà, IT		
	gliomas: Is there a role for surgery?	P. Mortini, IT		

16:30 Treatment options for recurrent gliomas: Is there a role for radiotherapy?
 M. Brada, UK
 17:00 Overview on palliation in neuro-oncology
 C. Gamondi, CH

17:30 GROUP WORKSHOPS

Group 1:

• Clinical cases presentations by the participants Chair: R. Rudà, IT

Group 2:

• Clinical cases presentations by the participants Chair: D. Bosetti, CH

Group 3:

• Clinical cases presentations by the participants Chair: R. Banghoo, UK

20:30 Farewell dinner

Saturday, 22 September _____

12:00 *Lunch*

8:30 EXTRA-AXIAL PRIMARY BRAIN TUMORS		Chair: P. Mortini, IT
9:00 9:30	Neuropathology: Update in 2016 WHO classification EANO guidelines on diagnosis and treatment	F. Roncaroli, UK
	options of EAPBT	R. Goldbrunner, DE
9:30	Neuro-surgery: State of the Art	P. Mortini, IT
10:00	Coffee break	
10:30	Radiation therapy: State of the Art	D. Bosetti, CH
11:00	Medical Therapy of Meningeomas	R. Soffietti, IT
11:30	Round table: Observation, surgery or radiotherapy/	Speakers: D. Bosetti, CH
	radiosurgery as a first approach in incidental PBT	M. Reinert, CH – R. Soffietti, IT

13:00 13:20		R. Rudà, IT
	on immunotherapy	P. Roth, CH
13:40	Best cases awards	G. Pesce, CH - P. Mortini, IT
14:10	Closing Remarks	G. Pesce, CH - P. Mortini, IT

13:00 SYSTEMIC TREATMENTS IN NEURO-ONCOLOGY Chairs: P. Roth, CH - R. Rudà, IT

GENERAL INFORMATION

ORGANISING SECRETARIAT

European School of Oncology Piazza Indipendenza 2 | 6500 Bellinzona | Switzerland Luis Carvalho

Ph: +41 91 820 0958 | Fax: +41 91 820 0953

E-mail: lcarvalho@eso.net

APPLICATIONS

Laura Richetti Ph: +41 91 820 0951 E-mail: lrichetti@eso.net

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY APPLICATION DEADLINE: 27 MAY 2018

Information and online application are available at www.eso.net

PARTICIPATION

Attendance is limited to 50 participants and admittance is by competitive application only. Successful applicants are granted free registration but a contribution to the costs of half board accommodation (farewell dinner included) at the course venue (EUR 300) is requested. Travel, arrival and departure transfers are to be covered by the participants.

ACCREDITATION

Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Information on the status of the application can be obtained from the organising secretariat. Participants will receive their certificate of attendance via e-mail after the event on completion of the evaluation form.

HOW TO APPLY

Applications should be submitted on-line at http://bit.ly/2GE2ii1 by providing the following documents:

- Letter describing motivation for attending the Masterclass
- Short CV (maximum 2 pages)
- Supporting letter from Head of Department/Mentor
- Clinical case abstract (template available online)
- Template professional experience (template available online)

The application outcome will be notified by e-mail at the end of June.

Clinical case abstract

The abstract should include the following criteria:

- Should describe a clinical case relating to the subject of the Masterclass, in the format of a clinical grand round rather than a publication article.
- Should include three questions relating to the clinical case that the applicant puts to the faculty for discussion.
- Should describe a case that reflects the applicant's daily practice. Uncommon or extremely rare cases are should be avoided.
- Should NOT report trials or research projects.